The fallen pharma giant could make a big comeback in 2026.Wall Street analysts can't agree on Novo Nordisk (NVO -2.96%), with Morgan Stanley recently cutting its rating to underweight on the back of disappointing growth in key prescriptions in the U.S., and HSBC Holdings recently raising its rating to a buy on the strength of the potential of its pipeline. Who's right? Novo Nordisk is a speculative buy.The HSBC approach, in this case, may be sensible, at least on a risk-reward basis. The nearly 50% drop in ...